tradingkey.logo
tradingkey.logo
Search

Ultragenyx Pharmaceutical Inc

RARE
Add to Watchlist
14.510USD
+0.010+0.07%
Close 09-18 16:00ET
1.43BMarket Cap
LossP/E TTM

Ultragenyx Pharmaceutical Inc (RARE) Revenue Performance

Updated: Jun 30, 2026

Last year, Ultragenyx Pharmaceutical Inc generated 304.00M USD for its biggest-performing segment, Crysvita royalty revenue. The North America made the largest contribution, accounting for 377.00M USD last year. For the latest quarter, Ultragenyx Pharmaceutical Inc reported the revenue of 102.00M USD for the period ending 2026-06-30, which came from the top-performing segment, Crysvita royalty revenue. North America contributed the highest revenue, at 121.00M USD.

By Business

Annual
Annual
Quarterly
Crysvita royalty revenue
Crysvita
Dojolvi
Evkeeza
Mepsevii
Daiichi Sankyo
Crysvita collaboration revenue in profit-share territory
Crysvita royalty revenue in European territory
Bayer
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
Crysvita royalty revenue
304.00M(45.17%)
274.81M(49.05%)
182.65M(42.06%)
21.69M(5.97%)
17.95M(5.11%)
12.99M(4.79%)
Crysvita
177.00M(26.30%)
134.71M(24.05%)
75.70M(17.43%)
42.68M(11.75%)
21.42M(6.10%)
10.35M(3.82%)
Dojolvi
96.00M(14.26%)
88.19M(15.74%)
70.63M(16.27%)
55.61M(15.31%)
39.56M(11.26%)
13.03M(4.81%)
Evkeeza
59.00M(8.77%)
32.16M(5.74%)
3.64M(0.84%)
--(--)
--(--)
--(--)
Mepsevii
37.00M(5.50%)
30.35M(5.42%)
30.44M(7.01%)
20.64M(5.68%)
16.04M(4.56%)
15.34M(5.66%)
Daiichi Sankyo
--(--)
--(--)
1.48M(0.34%)
7.69M(2.12%)
85.00M(24.19%)
89.22M(32.92%)
Crysvita collaboration revenue in profit-share territory
--(--)
--(--)
69.70M(16.05%)
215.02M(59.18%)
171.20M(48.72%)
128.60M(47.45%)
Crysvita royalty revenue in European territory
--(--)
--(--)
--(--)
--(--)
244.00K(0.07%)
1.50M(0.55%)
Bayer
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)

By Region

Annual
Annual
Quarterly
North America
Latin America
Europe Middle East and Africa
Asia Pacific
North America
Europe
Japan
others
United States
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
North America
377.00M(56.02%)
--(--)
--(--)
--(--)
--(--)
--(--)
Latin America
170.00M(25.26%)
130.71M(23.33%)
77.34M(17.81%)
44.71M(12.31%)
--(--)
--(--)
Europe Middle East and Africa
108.00M(16.05%)
--(--)
--(--)
--(--)
--(--)
--(--)
Asia Pacific
18.00M(2.67%)
--(--)
--(--)
--(--)
--(--)
--(--)
North America
--(--)
340.46M(60.77%)
307.15M(70.73%)
281.09M(77.36%)
301.11M(85.69%)
--(--)
Europe
--(--)
80.12M(14.30%)
47.53M(10.95%)
36.37M(10.01%)
26.66M(7.59%)
21.32M(7.87%)
Japan
--(--)
8.93M(1.59%)
2.22M(0.51%)
1.16M(0.32%)
--(--)
--(--)
others
--(--)
--(--)
--(--)
--(--)
23.64M(6.73%)
12.05M(4.44%)
United States
--(--)
--(--)
--(--)
--(--)
--(--)
237.67M(87.69%)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.